Sulfate is the active ingredient.
Acute lymphoblastic leukemia (ALL)
Hodgkin's lymphoma
NonHodgkin's lymphoma
Neuroblastoma
Rhabdomyosarcoma
Wilms' tumor
Other solid tumors (in combination with other chemotherapeutic agents)
Vinlon 1mg Inj (Vincristine) is a vinca alkaloid antineoplastic agent. It inhibits microtubule assembly, preventing cell division and ultimately leading to cell death. This effect is particularly pronounced in rapidly dividing cancer cells.
Store at controlled room temperature (20°C to 25°C) (68°F to 77°F). Protect from light. Dispose of unused medication properly according to local regulations. Never flush down the toilet.
Dosage is determined by the physician based on the patient's weight, age, overall health, and the specific cancer being treated.
It's typically administered intravenously (IV) by a healthcare professional.
Self-administration is not permitted.
Peripheral neuropathy (numbness, tingling, pain in the hands and feet)
Nausea and vomiting
Constipation
Hair loss
Mouth sores
Fatigue
Loss of appetite
Muscle weakness
Heart problems (rare but serious)
Alcohol consumption should be discussed with your doctor, as it may interact with the medication or worsen side effects.
Vincristine can cause fatigue, dizziness, and peripheral neuropathy which may impair coordination. Avoid driving or operating machinery if affected.
Vincristine is contraindicated in pregnancy and breastfeeding women due to its potential for severe harm to the fetus or infant.
Dosage is carefully adjusted for children based on their weight and the specific cancer being treated. Requires close monitoring.
Kidney function should be monitored, as vincristine is primarily eliminated by the kidneys. Dose adjustments may be necessary in patients with impaired renal function.
Liver function should be monitored, as vincristine metabolism can be affected by liver impairment. Dose adjustments may be necessary.
Physician's Desk Reference (PDR)
National Cancer Institute (NCI) website
Your Oncologist
